drugset / Trial / NCT00659178
Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to identify a dose of SB-485232 which is safe, tolerable and biologically active when used in combination with pegylated liposomal doxorubicin (Doxil) in patients with epithelial ovarian cancer. This study will use a standard treatment regimen of pegylated liposomal doxorubicin (Doxil) in combination with rising doses of SB-485232. The dose selected from this study will be used in a future studies to evaluate the efficacy of this combination.
Timeline
- Start
- 2008-06-18
- Primary completion
- 2011-02-18
- Completion
- 2011-02-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IBOCTADEKIN | Protein / enzyme biologic | — | — |
| Background | Doxorubicin | Other / unclassified | — | — |